Mechanisms and models in heart failure: the biomechanical model and beyond.

Received August 25, 2004; revision received December 23, 2004; accepted January 19, 2005. Despite repeated attempts to develop a unifying hypothesis that explains the clinical syndrome of heart failure, no single conceptual paradigm for heart failure has withstood the test of time. Whereas clinicians initially viewed heart failure as a problem of excessive salt and water retention that was caused by abnormalities of renal blood flow (the “cardiorenal model”1), as physicians began to perform careful hemodynamic measurements, it also became apparent that heart failure was associated with a reduced cardiac output and excessive peripheral vasoconstriction. This latter realization led to the development of the “cardiocirculatory” or “hemodynamic” model for heart failure,1 wherein heart failure was thought to arise largely as a result of abnormalities of the pumping capacity of the heart and excessive peripheral vasoconstriction. However, although both the cardiorenal and cardiocirculatory models for heart failure explained the excessive salt and water retention that heart failure patients experience, neither of these models explained the relentless “disease progression” that occurs in this syndrome. Thus, although the cardiorenal models provided the rational basis for the use of diuretics to control the volume status of patients with heart failure, and the cardiocirculatory model provided the rational basis for the use of inotropes and intravenous vasodilators to augment cardiac output, these therapeutic strategies have not prevented heart failure from progressing, nor have they led to prolonged life for patients with moderate to severe heart failure.1,2⇓ In the present review we will summarize recent advances in the field of heart failure, with a focus on the new therapeutic strategies that have been developed for treating systolic heart failure. For a complete discussion on recent advances in the diagnosis and treatment of diastolic heart failure, the interested reader is referred to several …

[1]  N. Hollenberg,et al.  Literature alert , 2002 .

[2]  H. Sabbah The cardiac support device and the myosplint: treating heart failure by targeting left ventricular size and shape. , 2003, The Annals of thoracic surgery.

[3]  H Harasaki,et al.  Structural and left ventricular histologic changes after implantable LVAD insertion. , 1995, The Annals of thoracic surgery.

[4]  M. Packer,et al.  Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia. , 1984, The New England journal of medicine.

[5]  S. Kardia,et al.  Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. , 2002, The New England journal of medicine.

[6]  M C Oz,et al.  Reversal of chronic ventricular dilation in patients with end-stage cardiomyopathy by prolonged mechanical unloading. , 1995, Circulation.

[7]  P. Doevendans,et al.  Stem cell therapy for ischemic heart disease. , 2003, Trends in molecular medicine.

[8]  M. Quiñones,et al.  Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. , 1995, Circulation.

[9]  Y. Hirota,et al.  [The natural history of dilated cardiomyopathy and pathophysiology of congestive heart failure]. , 1986, Journal of cardiography. Supplement.

[10]  B. Pitt,et al.  Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[11]  E. Foster,et al.  Effects of Long-Term Biventricular Stimulation for Resynchronization on Echocardiographic Measures of Remodeling , 2002, Circulation.

[12]  J. Cleland,et al.  Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure , 2004, Expert review of cardiovascular therapy.

[13]  M. Bristow,et al.  Inotropes and β-blockers: Is there a need for new guidelines? , 2001 .

[14]  D. Mann,et al.  Cardiocyte contractile performance in experimental biventricular volume-overload hypertrophy. , 1993, The American journal of physiology.

[15]  Chu-Pak Lau,et al.  Tissue Doppler Echocardiographic Evidence of Reverse Remodeling and Improved Synchronicity by Simultaneously Delaying Regional Contraction After Biventricular Pacing Therapy in Heart Failure , 2002, Circulation.

[16]  A. Feldman,et al.  Downregulation of Matrix Metalloproteinases and Reduction in Collagen Damage in the Failing Human Heart After Support With Left Ventricular Assist Devices , 2001, Circulation.

[17]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[18]  S. Tyagi,et al.  Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts , 1996, Molecular and Cellular Biochemistry.

[19]  S. Houser,et al.  Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. , 1998, Circulation.

[20]  J. Ross Mechanisms of cardiac contraction. What roles for preload, afterload and inotropic state in heart failure? , 1983, European heart journal.

[21]  Y. Sun,et al.  Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. , 1998, Circulation.

[22]  H. Ikram,et al.  DOUBLE-BLIND TRIAL OF CHRONIC ORAL BETA BLOCKADE IN CONGESTIVE CARDIOMYOPATHY , 1981, The Lancet.

[23]  H. Sabbah,et al.  Reversal of Chronic Molecular and Cellular Abnormalities Due to Heart Failure by Passive Mechanical Ventricular Containment , 2003, Circulation research.

[24]  Q. Li,et al.  Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. , 1998, The Journal of clinical investigation.

[25]  S. Kardia,et al.  Synergistic Polymorphisms of β1- and α2C-Adrenergic Receptors and the Risk of Congestive Heart Failure , 2002 .

[26]  A. Nitenberg,et al.  Coronary vasodilation induced by intracoronary enalaprilat: an argument for the role of a local renin-angiotensin system in patients with dilated cardiomyopathy. , 1989, European heart journal.

[27]  J. Chrast,et al.  Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. , 2004, The Journal of clinical investigation.

[28]  M. Bristow β-Adrenergic Receptor Blockade in Chronic Heart Failure , 2000 .

[29]  D. DeMets,et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.

[30]  D. Levy,et al.  Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. , 1997, The New England journal of medicine.

[31]  A. Quyyumi,et al.  Cardiac sympathetic nerve function in congestive heart failure. , 1996, Circulation.

[32]  G. Reeder Heart Disease: A Textbook of Cardiovascular Medicine , 1984 .

[33]  N Reichek,et al.  Left ventricular shape, afterload and survival in idiopathic dilated cardiomyopathy. , 1989, Journal of the American College of Cardiology.

[34]  R. Doughty,et al.  Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease , 1997 .

[35]  S. Vatner Reduced subendocardial myocardial perfusion as one mechanism for congestive heart failure. , 1988, The American journal of cardiology.

[36]  B. Groves,et al.  Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. , 1997, The Journal of clinical investigation.

[37]  B. Pau,et al.  Circulating cardiac troponin I in severe congestive heart failure. , 1997, Circulation.

[38]  S. Kumar,et al.  Differential gene expression of extracellular matrix components in dilated cardiomyopathy , 1996, Journal of cellular biochemistry.

[39]  D. Pimentel,et al.  Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. , 1998, Circulation.

[40]  H. Matsubara Risk to the coronary arteries of intracoronary stem cell infusion and G-CSF cytokine therapy , 2004, The Lancet.

[41]  H. Meiselman,et al.  Mean red cell volume as a correlate of blood pressure. , 1996, Circulation.

[42]  Richard J. Jones Heart Disease: A Textbook of Cardiovascular Medicine , 1980 .

[43]  J. Cohn Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. , 1995, Circulation.

[44]  D. Brutsaert,et al.  New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. , 2002, Circulation.

[45]  CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[46]  B. Kobilka,et al.  Two functionally distinct α2-adrenergic receptors regulate sympathetic neurotransmission , 1999, Nature.

[47]  L. Leinwand,et al.  Myosin heavy chain gene expression in human heart failure. , 1997, The Journal of clinical investigation.

[48]  W. Kiowski,et al.  Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. , 1997, Circulation research.

[49]  E. Braunwald Heart Disease: A Textbook of Cardiovascular Medicine , 1992, Annals of Internal Medicine.

[50]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[51]  Vincent Dor,et al.  The Endoventricular Circular Patch Plasty (“Dor Procedure”) in Ischemic Akinetic Dilated Ventricles , 2001, Heart Failure Reviews.

[52]  M. Bristow,et al.  Inotropes and beta-blockers: is there a need for new guidelines? , 2001, Journal of cardiac failure.

[53]  M. Bristow,et al.  Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. , 1996, Circulation.

[54]  R. Virmani,et al.  Apoptosis in myocytes in end-stage heart failure. , 1996, The New England journal of medicine.

[55]  E Erdmann,et al.  Intracellular Calcium Handling in Isolated Ventricular Myocytes From Patients With Terminal Heart Failure , 1992, Circulation.

[56]  M. Raynolds,et al.  Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. , 2000, Journal of molecular and cellular cardiology.

[57]  J. Towbin,et al.  Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy , 2002, The Lancet.

[58]  S. Vatner,et al.  Impaired regional subendocardial coronary flow reserve in conscious dogs with pacing-induced heart failure. , 1993, The American journal of physiology.

[59]  D. Mann,et al.  Mechanisms and models in heart failure: A combinatorial approach. , 1999, Circulation.

[60]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[61]  K. Adams,et al.  Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? , 2003, Journal of cardiac failure.

[62]  Bernd Westphal,et al.  Autologous bone-marrow stem-cell transplantation for myocardial regeneration , 2003, The Lancet.

[63]  D. Delurgio,et al.  Effect of Cardiac Resynchronization Therapy on Left Ventricular Size and Function in Chronic Heart Failure , 2003, Circulation.

[64]  D C Harrison,et al.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. , 1982, The New England journal of medicine.

[65]  Michael D. Schneider,et al.  Cardiac progenitor cells from adult myocardium: Homing, differentiation, and fusion after infarction , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[66]  P. Korner,et al.  Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. , 1986, Circulation.

[67]  K. Weber,et al.  Structural remodeling in hypertensive heart disease and the role of hormones. , 1994, Hypertension.

[68]  J. Bergsland,et al.  Partial left ventriculectomy to treat end-stage heart disease. , 1997, The Annals of thoracic surgery.

[69]  B. Massie 15 years of heart-failure trials: what have we learned? , 1998, The Lancet.

[70]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[71]  Gregory S. Nelson,et al.  Left Ventricular or Biventricular Pacing Improves Cardiac Function at Diminished Energy Cost in Patients With Dilated Cardiomyopathy and Left Bundle-Branch Block , 2000, Circulation.

[72]  C A Beltrami,et al.  Apoptosis in the failing human heart. , 1997, The New England journal of medicine.

[73]  Federica Limana,et al.  Mobilized bone marrow cells repair the infarcted heart, improving function and survival , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[74]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[75]  J. Schaper,et al.  Cardiomyocyte apoptosis in acute and chronic conditions , 1998, Basic Research in Cardiology.

[76]  G. Dorn,et al.  β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure , 2003, Nature Medicine.

[77]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[78]  M. Domanski,et al.  Effect of Baseline or Changes in Adrenergic Activity on Clinical Outcomes in the &bgr;-Blocker Evaluation of Survival Trial , 2004, Circulation.

[79]  A J LINZBACH,et al.  Heart failure from the point of view of quantitative anatomy. , 1960, The American journal of cardiology.

[80]  J. Holmes,et al.  Impaired subendocardial function in tachycardia-induced cardiac failure. , 1995, The American journal of physiology.

[81]  D. Zechner,et al.  Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. , 1996, The Journal of clinical investigation.

[82]  M. Pfeffer,et al.  Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON) , 2003, European journal of heart failure.

[83]  F. Spinale,et al.  Increased Matrix Metalloproteinase Activity and Selective Upregulation in LV Myocardium From Patients With End-Stage Dilated Cardiomyopathy , 1998 .

[84]  L. Stevenson,et al.  Medical management of advanced heart failure. , 2002, JAMA.

[85]  Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI) , 2002 .

[86]  G. Dorn,et al.  Interactions Between Phospholamban and &bgr;-Adrenergic Drive May Lead to Cardiomyopathy and Early Mortality , 2001, Circulation.

[87]  F. Clubb,et al.  Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. , 1998, Circulation.

[88]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[89]  H Harasaki,et al.  Left ventricular echocardiographic and histologic changes: impact of chronic unloading by an implantable ventricular assist device. , 1996, Journal of the American College of Cardiology.

[90]  B. Parsons,et al.  Adrenergic Effects on the Biology of the Adult Mammalian Cardiocyte , 1992, Circulation.

[91]  J Ross,et al.  Afterload mismatch in aortic and mitral valve disease: implications for surgical therapy. , 1985, Journal of the American College of Cardiology.

[92]  M. Bristow What Type of β-Blocker Should Be Used to Treat Chronic Heart Failure? , 2000 .

[93]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[94]  Jacques Melin,et al.  Cardiac Mechanics During Development of Heart-failure , 1993 .

[95]  James T. Willerson,et al.  Transendocardial, Autologous Bone Marrow Cell Transplantation for Severe, Chronic Ischemic Heart Failure , 2003, Circulation.

[96]  M. Acker,et al.  Rationale, design, and methods for a pivotal randomized clinical trial for the assessment of a cardiac support device in patients with New York health association class III-IV heart failure. , 2004, Journal of cardiac failure.

[97]  B. Fleischmann,et al.  Bone marrow–derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation , 2004, Nature Medicine.

[98]  R. Walsh,et al.  Effects of angiotensin II generated by an angiotensin converting enzyme-independent pathway on left ventricular performance in the conscious baboon. , 1995, The Journal of clinical investigation.

[99]  B. Carabello,et al.  Effects of chronic beta-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation. , 1994, The Journal of clinical investigation.

[100]  Won Yong Kim,et al.  Impact of Acute Biventricular Pacing on Left Ventricular Performance and Volumes in Patients with Severe Heart Failure , 2001, Cardiology.

[101]  D. Kass,et al.  Stabilization of chronic remodeling by asynchronous cardiomyoplasty in dilated cardiomyopathy: effects of a conditioned muscle wrap. , 1997, Circulation.

[102]  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. , 2001 .

[103]  J. Cohn,et al.  Prognostic Significance of Serial Changes in Left Ventricular Ejection Fraction in Patients With Congestive Heart Failure , 1993, Circulation.

[104]  M. Lohse,et al.  Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[105]  B. Nico,et al.  Right ventricular dysplasia: an ultrastructural study. , 1989, European heart journal.

[106]  J. S. Janicki,et al.  Cardiac myocyte necrosis induced by angiotensin II. , 1991, Circulation research.

[107]  M. Packer The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. , 1992, Journal of the American College of Cardiology.

[108]  C H Davies,et al.  Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. , 1995, Circulation.

[109]  R. Quaife,et al.  Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. , 2002, The New England journal of medicine.

[110]  T. R. I. Nvestigators A TRIAL OF THE BETA-BLOCKER BUCINDOLOL IN PATIENTS WITH ADVANCED CHRONIC HEART FAILURE , 2001 .

[111]  S. Bolling,et al.  Early outcome of mitral valve reconstruction in patients with end-stage cardiomyopathy. , 1995, The Journal of thoracic and cardiovascular surgery.

[112]  B. Bozkurt,et al.  New therapeutics for chronic heart failure. , 2002, Annual review of medicine.

[113]  J. Federman,et al.  Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. , 1984, Journal of the American College of Cardiology.

[114]  F. Beyersdorf,et al.  Endoventrikuläre Patchplastik bei Patienten mit idiopathischer, dilatativer Kardiomyopathie – eine Alternative zur Herztransplantation? , 2001, Zeitschrift für Kardiologie.

[115]  Hyun-Jai Cho,et al.  Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial , 2004, The Lancet.

[116]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[117]  O. Hess,et al.  Left ventricular function and myocardial structure in aortic valve disease before and after surgery. , 1984, Herz.

[118]  J. S. Janicki,et al.  Myocardial fibrosis: functional significance and regulatory factors. , 1993, Cardiovascular research.

[119]  W. Grossman,et al.  Evaluation and Management of Diastolic Heart Failure , 2003, Circulation.

[120]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[121]  M. Bristow Antiadrenergic therapy of chronic heart failure: surprises and new opportunities. , 2003, Circulation.

[122]  P. Grayburn,et al.  Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. , 1995, Journal of the American College of Cardiology.

[123]  D. Burkhoff,et al.  Chronic Unloading by Left Ventricular Assist Device Reverses Contractile Dysfunction and Alters Gene Expression in End-Stage Heart Failure , 2000, Circulation.

[124]  A. Friedl,et al.  Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy. , 1991, Circulation.

[125]  N. Hollenberg,et al.  Relation of the Renin‐Angiotensin-Aldosterone System to Clinical State in Congestive Heart Failure , 1981, Circulation.

[126]  O. Hess,et al.  Influence of collagen network on left ventricular systolic and diastolic function in aortic valve disease. , 1993, Journal of the American College of Cardiology.

[127]  F. Leclercq,et al.  Heart rate as a determinant of L-type Ca2+ channel activity: Mechanisms and implication in force-frequency relation , 1998, Basic Research in Cardiology.

[128]  Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. , 1994, Circulation.

[129]  Angelo Auricchio,et al.  Cardiac resynchronization therapy in heart failure. , 2005, Italian heart journal : official journal of the Italian Federation of Cardiology.

[130]  P. Wernet,et al.  Repair of Infarcted Myocardium by Autologous Intracoronary Mononuclear Bone Marrow Cell Transplantation in Humans , 2002, Circulation.

[131]  D. Brutsaert,et al.  New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. , 2002, Circulation.

[132]  G. Jennings,et al.  Adrenergic nervous system in heart failure. , 1997, The American journal of cardiology.

[133]  S. Goldstein,et al.  Left ventricular shape is the primary determinant of functional mitral regurgitation in heart failure. , 1992, Journal of the American College of Cardiology.

[134]  S. Stephen Unwanted effects of propranolol. , 1966, The American journal of cardiology.

[135]  David A. Williams,et al.  Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts , 2004, Nature.

[136]  John W. Adams,et al.  Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[137]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[138]  M. Domanski,et al.  A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. , 2003, Journal of cardiac failure.

[139]  E. Sonnenblick,et al.  Stretch-induced programmed myocyte cell death. , 1995, The Journal of clinical investigation.

[140]  K. Weber,et al.  Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. , 1997, Circulation.

[141]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[142]  S. Chugh,et al.  Isolated myocyte contractile function is normal in postinfarct remodeled rat heart with systolic dysfunction. , 1997, Circulation.